ArticleBMC ophthalmology2025
Ensemble machine learning algorithm for anti-VEGF treatment efficacy prediction in diabetic macular edema.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The evolving role of artificial intelligence in optimizing treatment and patient selection in diabetic macular edema.Indian journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiabetic macular edema (DME) is a leading cause of vision loss in diabetes, with variable responses to anti-vascular endothelial growth factor (anti-VEGF) therapy in DME patients. Current diagnosis relies on optical coherence tomography (OCT) imaging, but manual interpretation is limited. This study aims to integrate 3D-OCT features and clinical variables to develop machine learning (ML) models for predicting anti-VEGF treatment outcomes. METHODS AND ANALYSIS: Medical records and 3D-OCT images of DME patients were included in this study. The 3D-OCT images were categorized into good and poor visual response groups based on the best corrected visual acuity at one month after three consecutive anti-VEGF treatments. The images and clinical features were subjected to assessment by 11 automatic classification models for anti-VEGF treatment responses in DME patients. The top 3 performing models were selected to build an ensemble model, and evaluated in the test dataset.
resultsThis study included 142 patients with 3D-OCT images of 170 eyes. A total of 20 image and clinical features were selected for the model construction and test in DME patients responded to anti-VEGF therapy. Adaptive boosting (AdaBoost), GradientBoosting, and light gradient boosting machine (LightGBM) exhibited better performances than the remaining 8 models. The ensemble model constructed achieved a sensitivity of 0.941, specificity of 0.882, and accuracy of 0.912 in the test dataset, with an area under the receiver operating characteristic curve of 0.976.
conclusionThis study established an ensemble ML algorithm based on 3D-OCT images and clinical features for automatic detection of treatment responses to anti-VEGF treatment in DME patients to predict the efficacy of anti-VEGF treatment in DME patients and assist clinicians in optimal treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.